• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Adv Ther . Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals

tetano

Editor, Senior Moderator
Adv Ther


. 2024 Dec 16.
doi: 10.1007/s12325-024-03043-0. Online ahead of print. Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals

Christoph D Spinner[SUP] 1 [/SUP], Samira Bell[SUP] 2 [/SUP], Hermann Einsele[SUP] 3 [/SUP], Cécile Tremblay[SUP] 4 5 [/SUP], Michel Goldman[SUP] 6 [/SUP], Zain Chagla[SUP] 7 [/SUP], Axel Finckh[SUP] 8 [/SUP], Christopher J Edwards[SUP] 9 [/SUP], Igor Aurer[SUP] 10 [/SUP], Odile Launay[SUP] 11 [/SUP], Carolina Casañas I Comabella[SUP] 12 [/SUP], Samantha James[SUP] 13 [/SUP], Sabada Dube[SUP] 14 [/SUP], Katarzyna Borkowska[SUP] 12 [/SUP], Fungwe Jah[SUP] 15 [/SUP], Walid Kandeil[SUP] 16 [/SUP], Renata T C Yokota[SUP] 17 [/SUP], Cécile Artaud[SUP] 18 [/SUP], Jacques-Eric Gottenberg[SUP] 19 [/SUP], Loreto Gesualdo[SUP] 20 [/SUP], Dominique Bertrand[SUP] 21 [/SUP], Sofie Arnetorp[SUP] 22 [/SUP], Gkikas Magiorkinis[SUP] 23 [/SUP]



Affiliations
Abstract

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence of several variants during the pandemic has presented numerous challenges in preventing and managing this disease. The development of vaccines has played a pivotal role in controlling the pandemic, with a significant portion of the global population being vaccinated. This, along with the emergence of less virulent SARS-CoV-2 variants, has led to a reduction in the severity of COVID-19 outcomes for the overall population. Nevertheless, individuals with immunocompromising conditions continue to face challenges given their suboptimal response to vaccination and vulnerability to severe COVID-19. This expert review synthesizes recent published evidence regarding the economic and human impact of COVID-19 on such individuals. The literature suggests that rates of hospitalization, intensive care unit admission, and mechanical ventilation use were high during the pre-Omicron era, and remained high during Omicron and later, despite vaccination for this population. Moreover, studies indicated that these individuals experienced a negative impact on their mental health and health-related quality of life (HRQoL) compared to those without immunocompromising conditions, with elevated levels of anxiety, depression, and distress reported. Further, these individuals with immunocompromising conditions experienced substantial costs associated with COVID-19 and loss of income during the pandemic, though the evidence on the economic burden of COVID-19 in such individuals is limited. Generally, COVID-19 has increased healthcare resource use and costs, impaired mental health, and reduced HRQoL in those with varied immunocompromising conditions compared to both those without COVID-19 and the general population-underscoring the importance of continued real-world studies. Ongoing research is crucial to assess the ongoing burden of COVID-19 in vaccinated individuals with immunocompromising conditions who are still at risk of severe COVID-19 outcomes to ensure their needs are not disproportionately worse than the general population.

Keywords: COVID-19; Economic burden; Health-related quality of life; Humanistic burden; Immunocompromised; Mental health.

 
Back
Top